Literature DB >> 20392674

Analysis of intracellular doxorubicin and its metabolites by ultra-high-performance liquid chromatography.

Kumiko Sakai-Kato1, Eiko Saito, Keiko Ishikura, Toru Kawanishi.   

Abstract

Doxorubicin, a highly effective anticancer drug, produces severe side effect such as cardiotoxicity, which is mainly caused by its metabolite, doxorubicinol. While in vitro studies by measuring cellular concentration of doxorubicin have been reported, there have been no reports on measuring cellular concentration of the metabolites. In this report, we developed a sensitive and high-throughput method for measuring cellular concentrations of doxorubicin and its metabolites by ultra-high-performance liquid chromatography. The method achieved more than 96% recovery of doxorubicin and its metabolites from cell homogenates. Using simple separation conditions, doxorubicin and its three main metabolites, and the internal standard, were separated within 3 min. The method has a limit of quantification of 17.4 pg (32.0 fmol) injected doxorubicin. This high sensitivity enables the detection and intracellular quantification of doxorubicin and its metabolite, doxorubicinol, in cell homogenates, and its use will facilitate studies of the relationship between doxorubicin pharmacokinetics and therapeutic outcome. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20392674     DOI: 10.1016/j.jchromb.2010.03.040

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  6 in total

1.  High-Throughput Method for the Simultaneous Determination of Doxorubicin Metabolites in Rat Urine after Treatment with Different Drug Nanoformulations.

Authors:  Lara Zorić; Nikša Drinković; Vedran Micek; Leo Frkanec; Akif Emre Türeli; Nazende Günday-Türeli; Ivana Vinković Vrček; Ruža Frkanec
Journal:  Molecules       Date:  2022-02-09       Impact factor: 4.411

2.  A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of Doxorubicin.

Authors:  Katie F Maass; Chethana Kulkarni; Mohiuddin A Quadir; Paula T Hammond; Alison M Betts; Karl Dane Wittrup
Journal:  J Pharm Sci       Date:  2015-09-07       Impact factor: 3.534

3.  Simultaneous determination of doxorubicin and its dipeptide prodrug in mice plasma by HPLC with fluorescence detection.

Authors:  Jing Han; Jue Zhang; Haiyan Zhao; Yan Li; Zilin Chen
Journal:  J Pharm Anal       Date:  2015-12-31

4.  Hyperglycemia Promotes Chemoresistance Through the Reduction of the Mitochondrial DNA Damage, the Bax/Bcl-2 and Bax/Bcl-XL Ratio, and the Cells in Sub-G1 Phase Due to Antitumoral Drugs Induced-Cytotoxicity in Human Colon Adenocarcinoma Cells.

Authors:  Loredana Bergandi; Eleonora Mungo; Rosa Morone; Ornella Bosco; Barbara Rolando; Sophie Doublier
Journal:  Front Pharmacol       Date:  2018-08-13       Impact factor: 5.810

5.  Rapid and sensitive determination of doxorubicin in human whole blood by vertically-ordered mesoporous silica film modified electrochemically pretreated glassy carbon electrodes.

Authors:  Meifang Wang; Jing Lin; Jiawei Gong; Mingchen Ma; Hongliang Tang; Jiyang Liu; Fei Yan
Journal:  RSC Adv       Date:  2021-03-01       Impact factor: 3.361

6.  Analysis of the Doxorubicin and Doxorubicinol in the Plasma of Breast Cancer Patients for Monitoring the Toxicity of Doxorubicin.

Authors:  Yahdiana Harahap; Puspitasari Ardiningsih; Agatha Corintias Winarti; Denni Joko Purwanto
Journal:  Drug Des Devel Ther       Date:  2020-08-25       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.